Blood levels of adiponectin are low in patients with features of the metabolic syndrome [77], and treatment with thiazolidinediones (TZDs), which had been used to improve insulin sensitivity, result in increased adiponectin levels [78]. This evidence concerns the gene INS and metabolic syndrome.